Prosecution Insights
Last updated: April 18, 2026
Application No. 17/125,466

OCULAR TISSUE PERFORATION DEVICE

Non-Final OA §103
Filed
Dec 17, 2020
Examiner
MANNAN, MIKAIL A
Art Unit
3774
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Glaukos Corporation
OA Round
9 (Non-Final)
69%
Grant Probability
Favorable
9-10
OA Rounds
3y 6m
To Grant
92%
With Interview

Examiner Intelligence

Grants 69% — above average
69%
Career Allow Rate
208 granted / 302 resolved
-1.1% vs TC avg
Strong +24% interview lift
Without
With
+23.5%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
63 currently pending
Career history
365
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
44.8%
+4.8% vs TC avg
§102
26.2%
-13.8% vs TC avg
§112
21.4%
-18.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 302 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 2/5/26 has been entered. Response to Amendment This action is entered in response to Applicant's amendment and reply of 2/5/26. The claims 1-6, 10-13, and 21 are pending. The claim 1 is amended. Response to Arguments Applicant’s arguments, filed 2/5/26 with respect to the rejections of claims 1-4, 10, 13, and 21 under 103 as obvious over Badawi (US2013/0253438) in view of Hammack (WO2012/051575) and Akahoshi (US2010/0010419) have been fully considered but the arguments and are partially persuasive. Applicant argues, the modification with Hammack fails to teach or suggest the amended limitation of “a collar comprising a first end and a second end, wherein the first end spaced from the distal cannula end by at most 350 micrometers, such that the distal cannula end is configured to be advanced into at least trabecular meshwork, accessed via an anterior chamber, at a penetration depth limited by the first end of the collar”. Applicants reasoning is that the sleeve 35 is configured to be advanced into tissues as recited on page 14, lines 2-5 of Hammack. Applicant then concludes modifying Hammack such that the penetration depth is limited by the first end of the collar would be adverse to the teachings of Hammack. Examiner agrees, and the previous interpretation has been overcome. However, Hammack teaches a device extending to a penetrating needle and having a seal 55 (collar) disposed about the outside of the needle (see Fig. 15). Where the seal 55 has a tissue contacting surface to stop the main shaft from extending too far a length into the tissue, where the preferred lengths of the main shaft are from the distal edge 53 of the lumen to the seal 55 (Page 15, lines 5-15). Therefore, Hammack under a different interpretation teaches the newly amended claim limitations. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1-4, 10, 13, and 21 are rejected under 35 U.S.C. 103 as obvious over Badawi (US2013/0253438) in view of Hammack (WO2012/051575) and Akahoshi (US2010/0010419). Regarding claim 1, Badawi discloses an instrument to perforate ocular tissue (cannula is inserted into the eye tissue, Paragraph [0017, 0060]), the instrument comprising: a handle (202) configured to be grasped by a user (Paragraph [0080]), the handle including a proximal handle end (portion near grip 204) and a distal handle end (portion near housing 208) (see Fig. 2); and a dissection cannula (212) configured to core intraocular tissue (conduit may be used to remove tissue and would therefore be capable of coring intraocular tissue, Paragraph [0053]), the dissection cannula including: a proximal shaft end (where cannula 212 is coupled to housing, see Fig. 2) configured to interface with the handle (proximal end of cannula is coupled and extends from housing distal end, Paragraph [0053], see Fig. 2); a distal cannula end (distal curved portion 304) including an opening into a cannula bore (opening at the distal tip 306, see Fig. 3; where the cannula has a lumen that extends to the distal tip, Paragraph [0014]; Note Fig 3 shows the cannula of an exemplary delivery system, and Figure 2 depends an exemplary delivery system Paragraph [0080, 0081]); and an indicator (indicators may be used any portion of the system to identify the location of the distal end of the cannula, Paragraph [0053]; Note Fig 3 shows the cannula of an exemplary delivery system, and Figure 2 depends an exemplary delivery system Paragraph [0080, 0081]), wherein the dissection cannula is fixed with respect to the handle (fixed longitudinally with respect to the handle by being threaded to the distal end of the cannula, Paragraph [0057], see threads shown in Fig. 10B). Badawi is silent regarding a collar disposed around at least a portion of the outside of the dissection cannula, the collar comprising a first end and a second end, wherein the first end is spaced from the distal cannula end by at most 350 micrometers, such that the distal cannula end is configured to advanced into at least trabecular meshwork, accessed via an anterior chamber, at a penetration depth limited by the first end of the collar. However, Badawi teaches the cannula within the eye (Paragraph [0060]); and teaches indicators being on any portion of the system to identify the distal end of the cannula (Paragraph [0053]). Hammack teaches devices to access suprachoroidal space (anterior portion of the eye, see background of invention). The device having a seal 55 (collar) disposed about the outside of the needle (see Fig. 15). The seal 55 having a first end and a second end (see annotated Fig. 15), the first end spaced from the distal cannula end by some distance (see Fig. 15). Where the seal 55 has a tissue contacting surface to stop the main shaft from extending too far a length into the tissue, where the preferred lengths of the main shaft are from the distal edge 53 of the lumen to the seal 55 (Page 15, lines 5-15). It would have been obvious to one having ordinary skill in the art at the effective filing date of the application to have substituted the collar comprising a first end and a second end, around the cannula that indicates a spacing (penetration depth) from the distal end of the cannula, as taught by Hammack, for the indicator spaced from the distal end of the cannula as taught by Badawi, since the substitution would have the same predictable result of determining an penetration depth of the cannula and the collar of Hammack. Where the modified invention of Badawi with Hammack would be capable of being advanced into at least trabecular meshwork accessed via an anterior chamber. Where the modified invention of Badawi/Hammack is intended to be advanced into ocular tissue, and has the capability of accessing the anterior chamber and advancing into trabecular meshwork as disclosed by Badawi ([0004]), at a penetration depth indicated by the spacing as defined by the seal 55 (Page 15, line 15). Where the distal cannula end and the collar have the capability to be inserted into the anterior chamber of the eye when the penetration depth of achieved. Hammack further teaches the length of the shaft being between 2.75mm to 3mm (2750 to 3000 micrometers) (Page 10, lines 10-12). Hammack teaches this length is a result effective variable, dependent on the anatomical dimensions and mechanical characteristics of the tissues to be penetrated (Page 10, lines 15-18). It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the length of the shaft to be less than 350 micrometers, since the length of the shaft is a result effective variable that can be modified dependent on the tissue to be penetrated and anatomical dimensions of the patient. It has been held that where the general conditions of a claim are disclosed in the prior art, discovering the optimum or workable ranges involves only routine skill in the art. In re Aller, 105 USPQ 233. Badawi is silent regarding the distal cannula end includes a cross-section at a distal most end, the cross-section defining a plane that is perpendicular to a major cannula axis, and wherein the cross-section of the distal cannula end comprises a geometrical shape. Badawi according to other embodiment teaches the cannula is formed to have a cross-sectional profile that is circular ([0059]) and different designs for the beveled distal end ([0063]). Akahoshi teaches a needle for accessing the eye ([0056]), where the needle tip 112 terminates in a cutting edge 116 formed by beveling a first portion 118 of the outer surface 108 and a second portion 120 of the inner surface 110 a sharpened and continuous tip edge 116 ([0069], see Fig. 14). Akahoshi further teaches a bevel 58 with a leading edge 56, similar to the bevel of Badawi is an obvious alternative as shown in Figs. 3 & 4. It would have been obvious to one having ordinary skill in the art at the effective filing date of the invention to have substituted the needle tip of Akahoshi for the needle tip of Badawi, since the substitution would have yielded the same predictable result of providing a needle tip for accessing eye tissue by piercing, and provide the added benefit of creating cutting surfaces in both the torsional and longitudinal directions (see Abstract of Akahoshi). PNG media_image1.png 366 606 media_image1.png Greyscale Regarding claim 2, Badawi/Hammack/Akahoshi makes obvious the instrument of claim 1, Akahoshi further teaches wherein the distal cannula end includes a beveled edge (bevel of first portion 118). Regarding claim 3, Badawi/Hammack/Akahoshi makes obvious the instrument of claim 2; yet, is silent regarding the beveled edge includes at least one of a single bevel. Akahoshi further teaches wherein the beveled edge includes at least one of a single bevel (see single bevel 96 of Fig. 9; Akahoshi). It would have been obvious to one having ordinary skill in the art at the effective filing date of the application to have modified the bevel edge to include a single bevel since Akahoshi teaches the embodiments are obvious variants. Regarding claim 4, Badawi/Hammack/Akahoshi makes obvious the instrument of claim 3, Akahoshi further teaches wherein the beveled edge is sloped toward an interior surface of the cannula (see Fig. 14, [0069] of Akahoski). Regarding claim 10, Badawi/Hammack/Akahoshi makes obvious the instrument of claim 1, Badawi further discloses comprising a pressure source (mechanism as described in Paragraph [0016]) in communication with the cannula bore to adjust pressure in the cannula bore - lumen of cannula may be pressurized, see Paragraphs [0016], [0029], [0119]). Regarding claim 13, Badawi/Hammack/Akahoshi makes obvious the instrument of claim 1, the modified invention further discloses wherein the handle is integral with the dissection cannula (Examiner interprets the handle being integral with the cannula by being of being connected in construction of the device, see Fig. 2, Paragraph [0080] of Badawi). Regarding claim 21, Badawi/Hammack/Akahoshi makes obvious the instrument of claim 1, the modified invention further discloses wherein the ocular tissue is trabecular meshwork (the ocular tissue is capable of being trabecular meshwork, Badawi discloses the ocular tissue accessed is near the trabecular meshwork, [0004]). Claims 5 and 6 are rejected under 35 U.S.C. 103 as obvious over Badawi (US2013/0253438) in view of Hammack (WO2012/051575) and Akahoshi (US2010/0010419) as applied to claim 1 above, and further in view of Lee (US5423330). Badawi/Hammack/Akahoshi is silent regarding a serrated edge extending about at least a portion of the distal end as recited in claim 5, or extending about the entire distal cannula end as recited in claim 6. Lee teaches a device for making an incision in the eye and insertion of instruments (C1:L38-40). The incision is performed by a cannula having a serrated edge that extends about the entire distal cannula end (the edge at the opening of the cutting member 24 may be serrated and adapted to make a hole, C4:L60-64, see Figs. 1-3 & 13). It would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to have modified the distal cannula end to have the entire edge be serrated, as taught by Lee, in order to facilitate holding, piercing and penetrating of tissue (C5:L62-65). Claims 11 and 12 are rejected under 35 U.S.C. 103 as obvious over Badawi (US2013/0253438) in view of Hammack (WO2012/051575) and Akahoshi (US2010/0010419) as applied to claim 10 above, and further in view of Smedley (US2002/0133168). Regarding claims 11 and 12, Badawi/Hammack/Akahoshi makes obvious the instrument of claim 10 as discussed above; yet, is silent regarding the pressure source is configured to generate enough negative pressure in the cannula bore to draw ocular tissue into the bore and cut the ocular tissue against the distal cannula end. Badawi teaches cutting and removing the trabecular meshwork and using a conduit to pull excised tissue back into the cannula during retraction (paragraph [0029]). Smedley teaches a device for placing a fluid shunt 10 in the eye for treatment of glaucoma (see Abstract). The device including a punch 42 having an inner tube 6 (cannula) within an outer tube 4. The inner tube ends in a circular blade 56 (paragraph [0066]), wherein the shunt 10 is held in place by negative pressure prior to delivery (paragraph [0083]). It would have been obvious to one having ordinary skill in the art at the effective filing date of the application to have modified the invention of Badawi/Hammack/Akahoshi to have the pressure source generate negative pressure, as taught by Smedley, in order to hold or release a structure within the cannula (paragraph [0083] of Smedley, paragraph [0029] of Badawi). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to MIKAIL A MANNAN whose telephone number is (571)270-1879. The examiner can normally be reached M-F 10-6. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Thomas Barrett can be reached at (571)272-4746. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MIKAIL A MANNAN/Examiner, Art Unit 3774 /SARAH W ALEMAN/Primary Examiner, Art Unit 3774
Read full office action

Prosecution Timeline

Dec 17, 2020
Application Filed
Sep 08, 2022
Non-Final Rejection — §103
Dec 15, 2022
Response Filed
Apr 04, 2023
Final Rejection — §103
Jun 15, 2023
Request for Continued Examination
Jun 23, 2023
Response after Non-Final Action
Jul 26, 2023
Non-Final Rejection — §103
Oct 30, 2023
Response Filed
Feb 13, 2024
Final Rejection — §103
Apr 26, 2024
Response after Non-Final Action
May 15, 2024
Request for Continued Examination
May 16, 2024
Response after Non-Final Action
Jun 01, 2024
Non-Final Rejection — §103
Jul 23, 2024
Applicant Interview (Telephonic)
Jul 24, 2024
Examiner Interview Summary
Sep 09, 2024
Response Filed
Dec 23, 2024
Final Rejection — §103
Mar 18, 2025
Request for Continued Examination
Mar 19, 2025
Response after Non-Final Action
Apr 30, 2025
Non-Final Rejection — §103
Jul 29, 2025
Examiner Interview Summary
Jul 29, 2025
Applicant Interview (Telephonic)
Aug 07, 2025
Response Filed
Nov 14, 2025
Final Rejection — §103
Feb 05, 2026
Request for Continued Examination
Feb 27, 2026
Response after Non-Final Action
Mar 31, 2026
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599386
DEVICES, SYSTEMS, AND METHODS FOR TREATING THE LEFT ATRIAL APPENDAGE
2y 5m to grant Granted Apr 14, 2026
Patent 12575849
ULTRASONIC SURGICAL INSTRUMENTS HAVING OFFSET BLADES
2y 5m to grant Granted Mar 17, 2026
Patent 12575921
STENT AND SLEEVE DEPLOYMENT
2y 5m to grant Granted Mar 17, 2026
Patent 12569338
DILATING INTRODUCER DEVICES AND METHODS FOR VASCULAR ACCESS
2y 5m to grant Granted Mar 10, 2026
Patent 12527576
REINFORCEMENT DEVICE FOR INTRASACCULAR TREATMENT OF AN ANEURYSM
2y 5m to grant Granted Jan 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

9-10
Expected OA Rounds
69%
Grant Probability
92%
With Interview (+23.5%)
3y 6m
Median Time to Grant
High
PTA Risk
Based on 302 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month